Biomea Fusion (BMEA) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Pipeline overview and clinical strategy

• Two oral small molecule candidates are in development: Icovamenib for diabetes and BMF-650 for weight loss/obesity.

• Icovamenib targets insulin-deficient and GLP-1 inadequately controlled type 2 diabetes, with two phase II trials (COVALENT-211 and COVALENT-212) underway.

• BMF-650, an oral GLP-1 receptor agonist, is being developed for weight loss with a favorable safety and pharmacokinetic profile.

• Key clinical catalysts include primary endpoint data for Icovamenib studies in Q4 2026 and mid-year or Q2 2026 weight loss data for BMF-650.

• The company retains full worldwide rights across all programs.

Clinical data and mechanism of action

• Icovamenib showed sustained A1C/HbA1c reduction for up to nine months post-treatment in insulin-deficient patients.

• The drug acts as a menin inhibitor, promoting beta cell proliferation and increased insulin production.

• Enhanced GLP-1 receptor and insulin expression was observed, with potential synergy when combined with semaglutide.

• Similar A1C improvements were seen in patients failing GLP-1 therapy, with increased endogenous insulin measured by C-peptide.

• BMF-650 demonstrated robust, dose-dependent weight loss in preclinical models.

Patient selection and trial design

• Patient selection for Icovamenib trials is based on A1C (7.5–10.5), BMI (<32), and failure of 1–3 prior medications.

• Inclusion criteria focus on adults with type 2 diabetes not achieving glycemic targets, with background therapy maintained unless rescue is required.

• Two phase II studies: COVALENT-211 for insulin-deficient patients and COVALENT-212 for those failing GLP-1 therapy.

• Trials maintain background therapy to isolate Icovamenib's effect, with primary endpoints at 26 weeks and secondary at 52 weeks.

• Enrollment for the 211 study is expected to be completed in four months, with primary endpoint data by year-end.